GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Cyclically Adjusted FCF per Share

BriaCell Therapeutics (BriaCell Therapeutics) Cyclically Adjusted FCF per Share : $-4.40 (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BriaCell Therapeutics's adjusted free cash flow per share for the three months ended in Jan. 2024 was $-0.463. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-4.40 for the trailing ten years ended in Jan. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 32.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BriaCell Therapeutics was 32.50% per year. The lowest was 3.20% per year. And the median was 21.80% per year.

As of today (2024-04-29), BriaCell Therapeutics's current stock price is $2.2497. BriaCell Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2024 was $-4.40. BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


BriaCell Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted FCF per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.48 -16.52 -10.61 -6.40 -5.14

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.33 -5.26 -5.14 -4.52 -4.40

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



BriaCell Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.463/125.4675*125.4675
=-0.463

Current CPI (Jan. 2024) = 125.4675.

BriaCell Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 -1.186 98.920 -1.504
201407 -3.102 99.315 -3.919
201410 -0.034 99.473 -0.043
201501 -2.091 98.209 -2.671
201504 -0.986 99.710 -1.241
201507 -0.739 100.579 -0.922
201510 -1.071 100.500 -1.337
201601 -0.979 100.184 -1.226
201604 -1.007 101.370 -1.246
201607 -0.954 101.844 -1.175
201610 -1.049 102.002 -1.290
201701 -0.922 102.318 -1.131
201704 -2.085 103.029 -2.539
201707 -0.544 103.029 -0.662
201710 -2.797 103.424 -3.393
201801 -2.184 104.056 -2.633
201804 -2.377 105.320 -2.832
201807 -1.814 106.110 -2.145
201810 -2.030 105.952 -2.404
201901 -0.868 105.557 -1.032
201904 -2.850 107.453 -3.328
201907 -1.383 108.243 -1.603
201910 -1.177 107.927 -1.368
202001 -0.173 108.085 -0.201
202004 0.083 107.216 0.097
202007 -0.545 108.401 -0.631
202010 -0.075 108.638 -0.087
202101 -0.205 109.192 -0.236
202104 -1.178 110.851 -1.333
202107 -0.127 112.431 -0.142
202110 -0.117 113.695 -0.129
202201 -0.162 114.801 -0.177
202204 -0.314 118.357 -0.333
202207 -0.214 120.964 -0.222
202210 -0.228 121.517 -0.235
202301 -0.255 121.596 -0.263
202304 -0.344 123.571 -0.349
202307 -0.686 124.914 -0.689
202310 -0.456 125.310 -0.457
202401 -0.463 125.468 -0.463

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


BriaCell Therapeutics  (NAS:BCTX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BriaCell Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3

BriaCell Therapeutics (BriaCell Therapeutics) Headlines

From GuruFocus

BriaCell CEO Letter to Shareholders

By Stock market mentor Stock market mentor 01-24-2023